Evolution of Advanced Combination Treatment in Inflammatory Bowel Disease.
Despite multiple new advanced therapeutic options for the treatment of inflammatory bowel disease (IBD), almost half of patients do not achieve clinical remission and the number requiring intestinal resection has not significantly changed in over 20 years. To address the therapeutic ceiling seen wit...
| Publicado en: | Gastroenterology & Hepatology Vol. 21; no. 12; pp. 745 - 757 |
|---|---|
| Autores principales: | , , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Gastro-Hep Communications, Inc
Dec2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=190641959&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 190641959 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15547914 6N5B jtl: Gastroenterology & Hepatology issn: 15547914 maglogo: N pubinfo: dt: Dec2025 vid: 21 iid: 12 pid: 72163 pub: Gastro-Hep Communications, Inc place: New York, New York artinfo: ui: 190641959 190641959 190641959 190641959 ppf: 745 ppct: 12 formats: fmt: @attributes: type: P tig: atl: Evolution of Advanced Combination Treatment in Inflammatory Bowel Disease. aug: au: Jajoo, Arpita Margolin, Katherine Limketkai, Berkeley N. Parian, Alyssa affil: Division of General Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland sug: subj: Inflammatory Bowel Diseases Drug Therapy Inflammatory Bowel Diseases Pathology Biological Products Therapeutic Use Small Molecules Therapeutic Use Patient Safety Disease Remission Treatment Outcomes Immunologic Factors Therapeutic Use Adrenal Cortex Hormones Therapeutic Use ab: Despite multiple new advanced therapeutic options for the treatment of inflammatory bowel disease (IBD), almost half of patients do not achieve clinical remission and the number requiring intestinal resection has not significantly changed in over 20 years. To address the therapeutic ceiling seen with single-agent biologics or small molecules, clinicians have attempted combination therapy, known as advanced combination treatment (ACT), to target multiple inflammatory pathways involved in IBD pathogenesis. ACT may be particularly helpful for patients with long-standing refractory disease and those with extraintestinal manifestations. Initial trials have supported the safety and efficacy of ACT, showing clinical and endoscopic remission rates of 59% and 34%, respectively, and response rates of 69% and 43%, respectively, and few new safety signals. However, increased adverse events are seen in patients combining ACT and immunomodulators or corticosteroids. Conclusions are limited by the lack of robust randomized controlled trial evaluation and aggregate analysis of outcomes. This article will review the available data on the use of specific ACT regimens in IBD. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|